# US 2013/0273031 A1 · Novel anti-igf-ir antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273031 A1
- Document ID: US20130273031A1
- Status: Published application
- Kind: A1
- Application number: 13/777,040
- Filed: 2013-02-26
- Published: 2013-10-17
- Earliest claimed: 2002-01-18
- Assignees: Institute De Recherche Pierre Fabre; Merck Sharp & Dohme Corp.
- Applicants: Institute De Recherche Pierre Fabre; Merck Sharp & Dohme Corp.
- Inventors: LILIANE GOETSCH; NATHALIE CORVAIA; OLIVIER LEGER; NELLY KUKLIN; MICHAEL CHASTAIN; DAVID G. BROOKS; LEE J. HELMAN
- Web page: https://patentgrep.com/patent/US20130273031A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6805: {the drug being a vinca alkaloid}
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6819: {Plant toxins}
- A61K 47/6847: {the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

## Claims

### Claim 1

A method for treating lung cancer in a human subject comprising administering a therapeutically effective amount of an isolated antibody or binding fragment thereof comprising three light chain complementarity determining regions comprising SEQ ID NOs: 2, 4 and 6, and three heavy chain complementarity determining regions comprising SEQ ID NOs: 8, 10 and 12; and trastuzumab.

### Claim 2 (depends on 1)

The method of claim 1 wherein the antibody or binding fragment thereof is an antibody.

### Claim 3 (depends on 2)

The method of claim 2 wherein the antibody is a humanized antibody.

### Claim 4 (depends on 2)

The method of claim 2 wherein the antibody is a monoclonal antibody.

### Claim 5 (depends on 1)

The method of claim 1 wherein the antibody or binding fragment thereof is a humanized antibody that comprises a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 65 and a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 79.
